Advanced Enzyme Technologies Limited, a leading specialty biotech company with global leadership in the manufacturing of enzymes, has reported consolidated Q2 FY21 sales up 8% Y-o-Y to Rs. 120.4 crore against Rs. 111.4 crore in Q2 FY20. 

 

Consolidated EBITDA for Q2 FY21 stands at Rs. 58.5 crore against Rs. 47.3 crore in Q2 FY20, up 24%. Consolidated EBITDA Margin for Q2 FY21 stands at 49% as against 42% in Q2FY20. Consolidated Q2 FY21 Net Profit rose by 21% at Rs. 38.6 crore against Rs. 31.8 crore in Q2 FY20. 

 

Advanced Enzyme Technologies is a research driven company with global leadership in the manufacturing of enzymes. The company is committed to provide eco-safe solutions to wide variety of industries like human care and nutrition, animal nutrition, baking, fruit & vegetable processing, brewing & malting, grain processing, protein modification, dairy processing, specialty applications, textile processing, leather processing, paper & pulp processing, biofuels, biomass processing, bio catalysis, etc. 

 

The company aims to provide side-effect-free healthcare and eco-safe industrial solutions to its customers globally, and is today, the largest producer of enzymes in Central Asia. Equipped with state-of-the-art seven manufacturing facilities and six research & development locations across India, Germany and US, Advanced Enzymes exports to 45+ countries across 6 continents and provides customized and effective enzyme solutions coupled with the best in technical advice and superior service.